MRK Today - Aug 06: Mixed Reactions to Guidance

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

MRK Today - Aug 06: Mixed Reactions to Guidance

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly neighborhood investor, and I’m breaking down what went down with Merck today. So, Merck (MRK) had a bit of a mixed bag today, closing down just about 0.18%. Not a huge drop, but still, it got a bit of a nudge into the red.

So, here’s the scoop. Merck reported its earnings, and while they beat quarterly estimates, they also cut guidance for the year. That’s always a tricky combo, right? Investors seemed to hit the sell button pretty quickly, even though there were some bright spots, like strong performance in their oncology segment. It’s like they couldn’t see the forest for the trees. Some folks were more focused on the lowered guidance rather than the fact that their new drug indications are looking promising.

Now, why the mixed vibes? Well, according to the buzz, the oncology strength is definitely a reason to keep an eye on Merck. They raised their profit guidance for 2026, which usually sounds good, but the cut in earnings forecasts made some investors nervous. It’s like, “Can we trust this?” People tend to panic a bit when they hear “lower guidance.” But hey, on the flip side, their new product is doing really well, like, way better than anyone expected. That’s a good sign for the long game.

And here’s a little nugget to keep in mind: there’s potential for a second-season dose of their RSV vaccine for kids under 2 if it gets approved. That could seriously shake things up for them.

So, all in all, Merck had a day that was kind of like a rollercoaster—some ups, some downs, and a lot of mixed feelings. Remember, this is just for your info and entertainment, not financial advice. Catch you later!

まだレビューはありません